Cervical cancer risk and use of depot-medroxyprogesterone acetate in Costa Rica.
The relationship between cervical cancer and the use of depot-medroxyprogesterone acetate (DMPA) was examined in a nationwide case-control study in Costa Rica. Cases were women ages 25-58 years of age with invasive squamous cell cancer (N = 149) or carcinoma in situ (CIS, N = 415) reported by the National Tumor Registry during 1982-84. Controls (N = 764) were randomly selected during a nationwide household survey. Using logistic regression, we adjusted for known risk factors for cervical cancer. DMPA use was associated with a risk of CIS of 1.1 (95% confidence interval 0.6-1.8) and a risk of invasive cancer of 1.4 (95% confidence interval 0.6-3.1). The slightly elevated risks observed may be the result of chance or a detection bias. One limitation of this study is that few women had used DMPA for longer than two years.
Oberle
M W
MW
Division of Reproductive Health, Centers for Disease Control, Atlanta, GA 30333.
Rosero-Bixby
L
L
Irwin
K L
KL
Fortney
J A
JA
Lee
N C
NC
Whatley
A S
AS
Bonhomme
M G
MG
D000328:Adult; D002278:Carcinoma in Situ / Q000139:chemically induced* / Q000453:epidemiology; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced* / Q000453:epidemiology; D003271:Contraceptive Agents, Female / Q000009:adverse effects*; D003364:Costa Rica; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000009:adverse effects / Q000031:analogs & derivatives*; D017258:Medroxyprogesterone Acetate; D008875:Middle Aged; D012044:Regression Analysis; D012307:Risk Factors; D002583:Uterine Cervical Neoplasms / Q000139:chemically induced* / Q000453:epidemiology
D003271:Contraceptive Agents, Female; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone